The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, is dedicated to advancing cancer research through cutting-edge scientific inquiry, translational innovation, and precision medicine initiatives. Its core mission centers on acc...
The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, is dedicated to advancing cancer research through cutting-edge scientific inquiry, translational innovation, and precision medicine initiatives. Its core mission centers on accelerating the discovery of cancer prevention strategies, diagnostic tools, and therapeutic interventions by supporting high-impact research across the biomedical spectrum. Strategic priorities include genomic characterization of tumors, clinical trial infrastructure, bioinformatics capacity building, and the development of clinical-grade biological products such as lentiviral vectors for cell and gene therapies. The agency also prioritizes equitable data collection practices, including sexual orientation and gender identity (SOGI) metrics, and works to improve patient engagement and healthcare delivery systems for cancer care populations.
The NCI frequently procures analytical laboratory instrumentation, research and development services in life sciences, and testing laboratory services to support its experimental and clinical research pipelines. It relies heavily on indefinite-delivery/indefinite-quantity (IDIQ) contracts and combined solicitation vehicles to secure scalable, long-term scientific support. Procurement often targets specialized expertise in bioinformatics, clinical trial management, and biologics manufacturing, with a preference for integrated service solutions that bridge basic science and clinical application.
The agency’s primary procurement focus lies in analytical instrument manufacturing, physical and life sciences R&D, and testing laboratories, reflecting its emphasis on laboratory infrastructure and data-driven discovery. It demonstrates a consistent preference for Small Business Administration (SBA) set-asides, particularly in bioinformatics and management consulting services, indicating a strategic commitment to fostering innovation from small, specialized vendors. Vendor relationships are typically long-term and collaborative, with recurring engagements for subject matter experts and technology platforms such as SnapGene software and genomic characterization systems.
Organized under the National Institutes of Health, the NCI operates nationally with no single physical headquarters, coordinating a decentralized network of research centers, laboratories, and contracted partners. It utilizes a mix of sole-source, competitive, and IDIQ procurement vehicles to meet its dynamic scientific demands, ensuring agility in responding to emerging cancer research priorities.
